There are many kinds of third-generation targeted drugs for lung cancer, mainly including ositinib, alectinib, loratinib and so on. 1. Oshitinib: Oshitinib is a kinase inhibitor of epidermal growth factor, this drug is well tolerated and mainly treats locally advanced or metastatic non-small cell lung cancer positive for epidermal growth factor exon 21 or 19. The main adverse effects include nausea, vomiting and other digestive symptoms. 2. Amitinib: Amitinib is the third generation of EGF kinase inhibitor independently developed by China. It can effectively control the disease development of lung cancer patients and prolong their survival period. The main side effects include gastrointestinal irritation and skin rash, and the drug is forbidden for men and women who are preparing for pregnancy. 3. Loratinib: This drug belongs to the third generation of ALK inhibitors. It is of great benefit to patients with non-small cell lung cancer who have developed ALK fusion, as well as patients who are ALK variant positive. Side effects of Loratinib are mainly seen in cholesterol, increased triglycerides, memory loss, and pneumonia. Patients who need to use targeted drugs should have their oncologist develop a drug and treatment plan based on their condition.